GlassScriptPhysician profile
Anh Tuyet Vu
NPI 1245737493
$1,192.44
in general payments reported to CMS, 2019-2025
15 companies · $910 in 2025
The $910 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $42.92 · 2024: $240 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,149.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $204.72 | 2022-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $173.05 | 2025 | Freestyle Libre |
| Kyowa Kirin, INC. | $135.01 | 2025 | |
| Amgen INC. | $124.99 | 2024 | Evenity |
| Ascendis Pharma Endocrinology INC | $121.84 | 2025 | Yorvipath |
| Abiomed | $114.93 | 2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.12 | 2025 | Jardiance |
| Cequr Corporation | $55.05 | 2025 | Cequr Simplicity |
| Lilly USA, LLC | $41.38 | 2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $41.24 | 2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $35.13 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Averitas Pharma INC. | $23.94 | 2025 | Qutenza |
| Paratek Pharmaceuticals, INC. | $16.07 | 2022 | |
| Si-Bone, INC. | $14.80 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.17 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anh Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.